Patents by Inventor Eric Adam

Eric Adam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method For Identifying And/Or Quantifying Anti-Infective Compounds
    Publication number: 20090203062
    Abstract: The present invention relates to a method for identifying and/or quantifying an anti-infective compound. Furthermore it relates to a method for identifying and/or quantifying a mutation in a virulence factor of a pathogen of a host organism that reduces the virulence of the pathogen to a unicellular test organism.
    Type: Application
    Filed: December 6, 2006
    Publication date: August 13, 2009
    Applicant: MERLION PHARMACEUTICALS SA
    Inventors: Mohammed Benghezal, Eric Adam, Stephanie Braillard, Christine Burn, Aurore Lucas, Jean-Pierre Paccaud, Emilio Valentino, Pierre Cosson
  • Crystallization of AKT3
    Patent number: 7303892
    Abstract: Provided are crystals relating to AKT3 and its various uses.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: December 4, 2007
    Assignee: Takeda San Diego, Inc.
    Inventors: Eric Adam, Oleg Brodsky, Mark W. Knuth, Jacek Nowakowski, Nikola P. Pavletich, Devon A. Thompson, Robert A. Wijnands
  • Screening and use of reagents which block or activate intein splicing utilizing natural or homologous exteins
    Publication number: 20070166745
    Abstract: In accordance with the present invention, there are provided selection systems and methods for screening for agents that control splicing of inteins in their native host protein (extein) or in homologous exteins. Specifically, there are provided positive genetic selection systems for the screening of agents which inhibit or activate protein splicing which comprise: a host cell containing a chromosomal gene encoding either a drug-resistant form of a target enzyme or a wild-type target enzyme, and a plasmid-borne gene encoding either a drug-sensitive form of the target enzyme, which is dominantly cytotoxic upon interaction with the drug, or a dominantly cytotoxic form of the target enzyme. In these systems the plasmid-borne gene contains an intein, and the inhibition or activation of splicing of the dominant cytotoxic form of the target enzyme by a given reagent results in the survival or death of the host cell. More specifically, positive genetic selection systems that utilize the M. xenopi GyrA intein or M.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 19, 2007
    Applicant: New England Biolabs, Inc.
    Inventors: Francine Perler, Eric Adam
  • Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
    Patent number: 5834247
    Abstract: The present invention is directed to modified proteins and methods of their production. The modified proteins comprise a controllable intervening protein sequence (CIVPS) inserted into or adjacent a target protein, the CIVPS being capable of excision from or cleavage of the modified protein under predetermined conditions in cis or in trans, i.e., increase in temperature, exposure to light, unblocking of amino acid residues by dephosphorylation, treatment with chemical reagents or deglycosylation. If desired, the modified protein can be subjected to these conditions. The CIVPS may also be inserted into a region that substantially inactivates target protein activity. The CIVPS may be used in a number of applications including purification of the target protein in a one-step protocol.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: November 10, 1998
    Assignee: New England Biolabs, Inc.
    Inventors: Donald G. Comb, Francine B. Perler, William E. Jack, Ming-Qun Xu, Robert A. Hodges, Christopher J. Noren, Shaorong S. C. Chong, Eric Adam, Maurice Southworth